Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 9/20 | 0.40 |
| ▸ | BID | P55957 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921555 | 0.91 | BCL2A1 (0.39) | BCL2A1BIDALDH1A1NPC1RAB9A | |
| SCHEMBL9994269 | 0.85 | GRM2 (0.39) | GRM2ALDH1A1GFER | |
| SCHEMBL6921795 | 0.85 | GRM2 (0.46) | GRM2BCL2A1NPC1RAB9A | |
| SCHEMBL6922267 | 0.84 | GRM2 (0.48) | GRM2BCL2A1BIDALDH1A1 | |
| SCHEMBL6920958 | 0.83 | GRM2 (0.45) | GRM2BCL2A1 | |
| SCHEMBL6923042 | 0.83 | RAB9A (0.39) | GRM2BCL2A1NPC1RAB9A | |
| SCHEMBL6922513 | 0.82 | RXFP1 (0.45) | GRM2ALDH1A1RAB9A | |
| SCHEMBL6922377 | 0.81 | LMNA (0.41) | GRM2BCL2A1NPC1RAB9A | |
| SCHEMBL6923721 | 0.80 | NPC1 (0.40) | GRM2ALDH1A1NPC1RAB9A | |
| SCHEMBL6923330 | 0.77 | KDM4E (0.58) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | GRM2 2/4885BCL2A1 3768/4885BID 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.